Esperion therapeutics, inc. (ESPR)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities
Net income (loss)

-97,165

-201,810

-166,988

-74,978

-49,784

-36,375

-26,088

-11,742

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation expense

300

300

300

252

236

160

71

139

Amortization of debt discount

-

-

-

-

29

15

459

117

Amortization of debt issuance costs

-

-

-

-

32

16

19

15

Accretion of premiums and discounts on investments

200

217

-334

-1,014

-647

-202

-47

-

Non-cash interest expense related to the revenue interest liability

8,120

-

-

-

-

-

-

-

Revaluation of warrants

-

-

-

-

-

-

2,587

-32

Noncash interest expense on convertible notes

-

-

-

-

-

-

459

1,370

Stock-based compensation expense

25,884

23,968

18,605

15,957

12,726

3,679

1,227

80

Loss related to assets held for sale

-

-

-

-

-

-29

-27

-87

Loss on sale of assets

-

-

-

-

-47

-2

148

3

Changes in assets and liabilities:
Prepaids and other assets

3,396

2,884

1,731

-139

1,275

264

-27

429

Deferred revenue

2,152

-

-

-

-

-

-

-

Accounts payable

-16,055

24,446

15,758

3,888

-1,333

-299

1,756

-215

Other accrued liabilities

10,000

7,594

2,462

5,998

519

814

1,443

-195

Net cash (used in) provided by operating activities

-70,341

-148,638

-131,302

-47,730

-38,156

-32,021

-18,114

-10,808

Purchases of investments

34,326

25,481

219,577

197,230

280,559

48,088

24,677

-

Proceeds from sales/maturities of investments

99,510

166,081

183,743

207,442

120,792

12,351

3,505

-

Proceeds from sale of assets

-

-

-

-

24

12

201

5

Purchase of property and equipment

953

151

19

94

325

873

31

7

Net cash provided by investing activities

64,231

140,449

-35,853

10,118

-160,068

-36,598

-21,002

-2

Financing activities
Proceeds from issuance of common stock, net of issuance costs

124,424

-

164,000

-

189,983

91,731

72,194

-

Proceeds from issuance of preferred stock, net of issuance costs

-

-

-

-

-

-

16,824

-

Proceeds from exercise of common stock options

11,771

11,743

1,167

45

1,177

473

123

41

Proceeds from warrant issuance

-

-

-

-

-

78

-

298

Proceeds from debt issuance, net of issuance costs

-

-

-

-

-

4,838

-

15,412

Payments on long-term debt

-

1,049

1,709

1,604

638

-

-

-

Net cash provided by financing activities

136,195

10,694

163,458

-1,559

190,522

97,120

89,141

15,751

Net increase (decrease) in cash and cash equivalents

130,085

2,505

-3,697

-39,171

-7,702

28,501

50,025

4,941

Supplemental disclosure of cash flow information:
Purchase of property and equipment not yet paid

190

199

-

-

-

-

-

-

Non cash right of use asset

31

-

-

-

-

-

-

-

Offering costs not yet paid

-

-

22

-

-

-

-

-